WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 26, 2016

Primary Completion Date

April 7, 2017

Study Completion Date

April 7, 2017

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Aspirin

The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.

Trial Locations (1)

S57AU

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

All Listed Sponsors
lead

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER

NCT02741817 - WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS) | Biotech Hunter | Biotech Hunter